title: Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism.
abstract: There has been growing interest in the potential of the altered metabolic state typical of cancer cells as a drug target. The antidiabetes drug, metformin, is now under intense investigation as a safe method to modify cancer metabolism. Several studies have used window of opportunity in breast cancer patients before neoadjuvant chemotherapy to correlate gene expression analysis, metabolomics, immunohistochemical markers, and metabolic serum markers with those likely to benefit. We review the role metabolite measurement, functional imaging and gene sequencing analysis play in elucidating the effects of metabolically targeted drugs in cancer treatment and determining patient selection.
authors.affiliation: Department of Oncology (SRL, ALH) and Oxford Cancer Imaging Centre (NP, DL, JF, FG), Churchill Hospital, and Molecular Oncology Laboratories, Weatherall Institute for Molecular Medicine, John Radcliffe Hospital (SRL, FB, ALH), University of Oxford, Oxford, UK.
authors.forename: Simon R
authors.initials: SR
authors.lastname: Lord
authors.affiliation: Department of Oncology (SRL, ALH) and Oxford Cancer Imaging Centre (NP, DL, JF, FG), Churchill Hospital, and Molecular Oncology Laboratories, Weatherall Institute for Molecular Medicine, John Radcliffe Hospital (SRL, FB, ALH), University of Oxford, Oxford, UK.
authors.forename: Neel
authors.initials: N
authors.lastname: Patel
authors.affiliation: Department of Oncology (SRL, ALH) and Oxford Cancer Imaging Centre (NP, DL, JF, FG), Churchill Hospital, and Molecular Oncology Laboratories, Weatherall Institute for Molecular Medicine, John Radcliffe Hospital (SRL, FB, ALH), University of Oxford, Oxford, UK.
authors.forename: Dan
authors.initials: D
authors.lastname: Liu
authors.affiliation: Department of Oncology (SRL, ALH) and Oxford Cancer Imaging Centre (NP, DL, JF, FG), Churchill Hospital, and Molecular Oncology Laboratories, Weatherall Institute for Molecular Medicine, John Radcliffe Hospital (SRL, FB, ALH), University of Oxford, Oxford, UK.
authors.forename: John
authors.initials: J
authors.lastname: Fenwick
authors.affiliation: Department of Oncology (SRL, ALH) and Oxford Cancer Imaging Centre (NP, DL, JF, FG), Churchill Hospital, and Molecular Oncology Laboratories, Weatherall Institute for Molecular Medicine, John Radcliffe Hospital (SRL, FB, ALH), University of Oxford, Oxford, UK.
authors.forename: Fergus
authors.initials: F
authors.lastname: Gleeson
authors.affiliation: Department of Oncology (SRL, ALH) and Oxford Cancer Imaging Centre (NP, DL, JF, FG), Churchill Hospital, and Molecular Oncology Laboratories, Weatherall Institute for Molecular Medicine, John Radcliffe Hospital (SRL, FB, ALH), University of Oxford, Oxford, UK.
authors.forename: Francesca
authors.initials: F
authors.lastname: Buffa
authors.affiliation: Department of Oncology (SRL, ALH) and Oxford Cancer Imaging Centre (NP, DL, JF, FG), Churchill Hospital, and Molecular Oncology Laboratories, Weatherall Institute for Molecular Medicine, John Radcliffe Hospital (SRL, FB, ALH), University of Oxford, Oxford, UK. adrian.harris@oncology.ox.ac.uk.
authors.forename: Adrian L
authors.initials: AL
authors.lastname: Harris
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D017024:Chemotherapy, Adjuvant / Q000379:methods; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D055442:Metabolome / Q000187:drug effects; D008687:Metformin / Q000627:therapeutic use*; D020360:Neoadjuvant Therapy / Q000379:methods*; D059467:Transcriptome / Q000187:drug effects
chemical_list: D014408:Biomarkers, Tumor; D007004:Hypoglycemic Agents; D008687:Metformin